Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom

Conclusions As per base-case analyses, an adequate discount on ibrutinib is required to make it cost-effective as per the UK thresholds. The scenario analysis substantiates ibrutinib’s cost-savings for the UK National Health Services and advocates patient’s access to ibrutinib in the UK. Teaser A Markov model was used to assess the cost-effectiveness of ibrutinib compared to obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results demonstrated ibrutinib not to be cost-effective. However, additional analyses demonstrated ibrutinib to be significantly cost-effective when compared to the current mode of care in which ibrutinib is administered as the second-line treatment.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research